DETOUR1 Clinical Trial Study: 24-Month Data Presented at VIVA
DETOUR1 Clinical Trial includes a 79% primary patency, with 82% of patients maintaining freedom from major adverse events at 2 years post-procedure.
DETOUR1 Clinical Trial includes a 79% primary patency, with 82% of patients maintaining freedom from major adverse events at 2 years post-procedure.
Copyright 2025 | All Rights Reserved | Medical Device News Magazine, is a Division of PTM Healthcare Marketing, Inc.